Bolt Biotherapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; balance-sheet comparisons are with December 31, 2023. Bolt is a clinical-stage oncology biopharmaceutical company. It reported no product-sales revenue; collaboration agreements were its sole revenue source.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Collaboration revenue | $5.274 million | $1.826 million |
| Research and development expense | $16.529 million | $14.625 million |
| General and administrative expense | $5.837 million | $5.616 million |
| Total operating expenses | $22.366 million | $20.241 million |
| Operating loss | $17.092 million | $18.415 million |
| Net loss | $10.811 million | $16.980 million |
| Basic and diluted loss per share | $0.28 | $0.45 |
| Net cash used in operating activities | $16.751 million | $23.399 million |
Revenue increased primarily because of the Innovent agreement amendment and continued collaboration work. R&D expense rose $1.904 million, mainly from clinical-trial, contract-service, and personnel costs, partly offset by lower manufacturing expense. The lower net loss reflected increased collaboration revenue and $4.675 million of other income, including a one-time $4.7 million Innovent payment. Interest income was $1.606 million, versus $1.435 million. No gross margin is reported; the filing does not provide a clear product-margin measure.
At March 31, 2024, cash, cash equivalents, and marketable securities totaled $112.8 million; accumulated deficit was $375.1 million. Cash, cash equivalents, and restricted cash were $6.027 million, including $1.765 million restricted cash. Total assets were $142.892 million and total liabilities were $38.733 million. The filing reports no outstanding debt; operating lease liabilities totaled $19.567 million, including current and non-current portions. Management believes existing cash and marketable securities will fund operations for at least 12 months following the report’s issuance. Bolt states it will need additional capital to advance its programs.
Material changes and business developments
- Q1 operating cash use declined by $6.648 million year over year. The company attributed 2024 operating cash use mainly to its net loss and decreases in deferred revenue, accounts payable, and accrued expenses.
- In March 2024, Bolt amended its Innovent collaboration, obtained exclusive worldwide rights to specified ISAC programs against two tumor targets, and assumed their future development and commercialization costs if pursued. It recognized $2.5 million of deferred revenue as collaboration revenue and the $4.7 million one-time payment as other income. Innovent may receive up to $112.7 million in milestones plus low-single-digit royalties.
- On May 14, 2024, after quarter-end, Bolt announced it would discontinue trastuzumab imbotolimod (formerly BDC-1001), whose Phase 2 program the company determined would not meet success criteria. It plans to focus on BDC-4182 and BDC-3042 and reduce operating expenses through a workforce reduction of approximately 50 employees, or 50% of staff. Estimated pre-tax restructuring charges are $3.0–$4.0 million, expected substantially in Q2 2024; the reduction is expected to be complete by year-end.
- BDC-3042 had completed its first three Phase 1 dose-escalation cohorts without dose-limiting toxicity, according to the filing. The planned strategy also prioritizes BDC-4182, targeting Claudin 18.2.
Outlook, risks, and contingencies
Management expects continued operating losses and significant R&D spending. Longer-term funding needs depend on clinical progress, portfolio priorities, collaboration outcomes, and access to financing; the company may need equity, debt, or partnering capital. Additional financing may dilute shareholders or require concessions on program rights. Key risks include clinical and regulatory uncertainty, ability to raise capital, reliance on single-source manufacturers and suppliers, macroeconomic disruption, and execution of the restructuring. Bolt cautions that actual cash needs could exceed its forecast.
Commitments include operating leases and up to $2.0 million in potential future EirGenix regulatory milestone payments. The company reported no material pending legal proceedings or material indemnification claims. Its $75.0 million at-the-market program had no shares sold through March 31, 2024. Management concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Whether the reported cash runway remains valid after the May 2024 program discontinuation, restructuring, and related charges.
- Execution and costs of the workforce reduction, including whether actual charges fall within the estimated $3.0–$4.0 million range.
- Clinical milestones, spending needs, and financing plans for BDC-4182 and BDC-3042.
- Future funding, development obligations, and potential economics under the amended Innovent agreement and continuing Genmab and Toray collaborations.
- Clinical and manufacturing commitments tied to the discontinued trastuzumab imbotolimod program, including trial wind-down costs and applicable collaboration terms.